ArticleAnnals of hematology2025
Prognostic value of dynamic minimal residual disease monitoring for adolescent and adult T-lymphoblastic leukemia/lymphoma.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Outcomes of T-cell lymphoblastic lymphoma in children and adolescents treated with Dana-Farber Cancer Institute Childhood ALL Consortium protocols.Frontiers in pediatrics · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is a high-risk malignancy with poor outcomes due to frequent relapse. The prognostic role of minimal residual disease (MRD) dynamic monitoring in adult T-ALL/LBL needs further validation across chemotherapy and transplantation phases. This large-scale study aimed to assess multi-timepoint MRD as a predictive biomarker, and integrated risk factors in adult T-ALL/LBL. 348 T-ALL/LBL patients treated with induction/consolidation chemotherapy ± allogeneic hematopoietic stem cell transplantation (allo-HSCT) were involved. MRD was assessed via multiparameter flow cytometry (MFC) at four landmark timepoints: post-induction (EOI-MRD), post-consolidation (EOC-MRD), pre-HSCT (pre-MRD), and post-HSCT (post-MRD). The prognostic value of routine clinical and laboratory variables was analyzed. The cohort exhibited 10-year OS and EFS rates of 35.0% and 28.2%, respectively. Adverse prognostic factors included thrombocytopenia (PLT ≤ 90 × 10⁹/L; p = 0.0195), elevated LDH (> 600 IU/L; p = 0.0338), cerebrospinal fluid (CSF) infiltration (p = 0.0012), and induction failure (p = 0.0237). HSCT improved outcomes (median OS: 24 vs. 17 months; p = 0.0007), especially in relapsed/refractory (R/R) patients (5-year OS: 40% vs. < 20%; p = 0.0042). MRD positivity predicted inferior survival at all timepoints (EOI-MRD: p = 0.0255; pre-HSCT: p = 0.0156; post-HSCT: p < 0.0001, 100% relapse if positive). Chemotherapy-only patients with sustained MRD negativity had a reduced relapse rate (p = 0.0090) and superior OS (p = 0.0001). In conclusion, dynamic MRD monitoring (pre-/post-HSCT and during chemotherapy) is prognostic in adult T-ALL/LBL. Combined with variables including LDH and MRD kinetics enables precision prognostication and guides therapeutic decision-making, including early HSCT for persistent MRD-positive cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.